Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

20211,451 citationsJournal Articlebronze Open Access

Authors

Aditya Bardia · Institut Claudius Regaud

Sara A. Hurvitz · University of California, Los Angeles

Sara M. Tolaney · Institut Claudius Regaud

Delphine Loirat · Institut Claudius Regaud

Kevin Punie · Institut Claudius Regaud

Mafalda Oliveira · Vall d'Hebron Institute of Oncology

Adam Brufsky

Abstract

Progression-free and overall survival were significantly longer with sacituzumab govitecan than with single-agent chemotherapy among patients with metastatic triple-negative breast cancer. Myelosuppression and diarrhea were more frequent with sacituzumab govitecan. (Funded by Immunomedics; ASCENT ClinicalTrials.gov number, NCT02574455; EudraCT number, 2017-003019-21.).

Topics & Keywords

HER2/EGFR in Cancer Research Cancer Treatment and Pharmacology Advanced Breast Cancer Therapies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 384, Issue 16, pp. 1529-1541

DOI: 10.1056/nejmoa2028485

Field-Weighted Citation Impact: 85.82